Business Wire

PITCH

20.5.2021 15:12:07 CEST | Business Wire | Press release

Share
Pitch Raises $85 Million To Build The First Complete Platform for Presentations

Pitch , the collaborative presentation platform for modern teams, today announced that it has raised an $85 million Series B funding round led by Lakestar and Tiger Global, and joined by existing Pitch investors Index Ventures and Thrive Capital.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210520005667/en/

Six months after launching to the public, the Series B investment comes at a time of significant growth and momentum for Pitch. To date, tens of thousands of teams have opened 125,000 workspaces on Pitch, including top companies like Intercom, Superhuman and Notion.

“Our mission at Pitch is to enable every team’s best thinking,” said Christian Reber, Founder & CEO of Pitch. “It’s been six months since we launched to the world, and tens of thousands of teams have already discovered how easy it is to create, collaborate on and deliver beautiful presentations on Pitch. We’re thrilled to have two world-class partners in Tiger Global and Lakestar onboard as we pursue our vision to build the first complete platform for presentations.”

A new kind of platform

To accelerate its momentum in the year ahead, Pitch plans to use the new funding to develop its core technology and product, grow its global team, and extend its software platform across the entire presentation workflow.

  • A publishing and content ecosystem: Pitch is building a dedicated home for publishing and exchanging presentations and templates. In this new ecosystem, users will be able to discover content from top creators and brands, and publish their own work directly to public profile pages. In the upcoming weeks, Pitch will launch the first of these pages for a select group of creators, and will open up access to all users later this year.
  • Advanced presentation analytics: Pitch is building new integrated solutions for users to better distribute presentations and monitor performance. Rolling out in multiple stages this summer, these new features will enable secure sharing and advanced analytics within Pitch, and will give users detailed insights into the reach and readership of a presentation, engagement levels on specific slides, and more.
  • Narrative recording and playback: Pitch is building new ways to highlight, record, and play back presentations in any context. Designed for a more remote, asynchronous world of work, these tools will ensure presenters and recipients can engage across an expanded range of meeting formats and team workflows. These tools are currently in beta, and will be rolled out in stages to users in the coming months.

“The exciting vision that Christian and the team at Pitch have is beyond just being a superior alternative to legacy presentation software," said Stephen Nundy, Partner at Lakestar. "A reimagining of the entire workflow surrounding presentations is very much overdue, and when coupled with the ability to harness new data and media integrations, Pitch will lead the way in changing how stories are told. I’m very proud to be joining the board of a European company with its sights set on a truly global opportunity.”

“We are incredibly impressed by the quality of Pitch’s offering today and Christian’s vision for the future. Pitch will be a true productivity platform, and we are excited to become investors in this special company,” says John Curtius, Partner at Tiger Global.

Pitch offers both free and paid plans for teams of all sizes. With Pitch Pro, teams unlock access to unlimited storage, video uploads, version history, and advanced permissioning for $10 per member per month.

About Pitch

Pitch is the collaborative presentation software for modern teams. With a focus on real-time collaboration, smart workflows, and intuitive design features, Pitch makes it fast and delightful for teams to create and deliver beautiful presentations, and easy for anyone to find inspiration from templates crafted by experts. Tens of thousands of teams have made the switch to Pitch, including top brands like Intercom, Superhuman, and Notion. Founded in 2018 by the team behind Wunderlist, and powered by a team of over 100 thinkers, makers, and storytellers, Pitch has raised over $135 million to date. To learn more and create a free account, visit pitch.com

About Lakestar

Lakestar is one of Europe's leading venture capital firms investing in technology companies led by exceptional entrepreneurs. The team’s early investments included Skype, Spotify, Facebook and airbnb. Since raising a first fund in 2013, Lakestar manages an aggregated volume of over EUR 1bn across three early stage funds, and more recently a growth fund. The company has expanded and broadened its portfolio and holds investments in the likes of Opendoor, Oscar, GYG, Glovo, Sennder, Eigen, FiveAI, Revolut and Hometogo to name a few. Lakestar has presence in Berlin, Zurich and London. Lakestar helps companies to identify new markets and expand into them rapidly, with a focus on the US and Europe. The team advises and supports portfolio companies in business development, recruitment, technology and marketing. The investments range from early stage companies to those in their growth stage. Visit us on LinkedIn and our website.

About Tiger Global Management

Tiger Global Management is a leading global technology investment firm with over $60 billion under management. The firm focuses on private and public companies in the internet, software, and financial technology sectors. Since 2001, Tiger Global has invested in hundreds of companies across more than 30 countries, including investments ranging from Series A to pre-IPO. The firm aims to partner with dynamic entrepreneurs operating market-leading companies in its core focus areas. Tiger Global’s investments have included JD.com, UiPath, Stripe, Databricks, Bytedance, Snowflake, Facebook, Alibaba, Procore, Chime, Blend, Peloton, Attentive, LinkedIn, Flipkart, and Toast.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye